

Curriculum vitae

Personal Information

Name Prof. Jian Li
Phone +86 13816999346
E-mail rmsl_2040@163.com



Education and Work Experience

2019.1~ Professor, School of Pharmacy, Gannan Medical University
2016.4-2018.6 Postdoctoral Researcher, College of Pharmacy, University of Kentucky, USA
2015.1-2016.3 Deputy Director of Structural Biology and Cardiovascular Disease Research Center, Shaanxi Provincial Key Laboratory of Ischemic Cardiovascular Disease, Xi 'an Medical University, Lecturer
2012.7-2014.12 Postdoctoral Fellow, Drug Design, Center for Drug Discovery and Design, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
2006.9-2012.7 Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai National Science Center for Light Source, Ph. D., Protein crystallography
2004.8-2006.8 State Key Laboratory of Proteomics, Beijing Proteomics Research Center, Beijing Institute of Radiation Medicine, Assistant Researcher
2000.9-2004.7 Shenyang University of Chemical Technology, Bachelor of Engineering, Biological Engineering

Social part-time job

2020.6-2023.6 Jiangxi Province high-tech enterprise identification and evaluation experts, Jiangxi Province high-tech enterprise identification management Leading Group Office.
2021.9.29 Member of the 2nd Applied Pharmacology Committee of Jiangxi Provincial Pharmaceutical Society.
2021.12.2 "Jiangxi Navigator" Think Tank Experts, Jiangxi Province industrial and information field expert database.

(Journal reviewer)

2022.4 Journal reviewer for *Cardiovascular Therapeutics*, *Progress in Biochemistry and Biophysics*, *Drug Design, Development and Therapy*, *Journal of Medicinal Chemistry*.

Academic Achievements

I have been engaged in innovative drug research and development and structural analysis of drug targets for more than 10 years, and have rich experience.

At present, I have published more than 100 drug target structures and 7 single particle cryo-electron microscope structures in the PDB database, analyzed the high-resolution three-dimensional structures of proteins related to several important disease targets, and discovered and optimized several small molecule inhibitors of different disease targets based on the structures.

I have published a total of more than 50 SCI papers, including PNAS and Nature communications, Science Advances, JMC, etc., with a total impact factor of more than 240 and more than 1000 citations, of which 14 were in the first region and 33 were first authors (including co-authors) or corresponding authors. I chaired and participated in a number of National Natural science foundations, and I have 4 invention patents.

I have been selected as one of the "Thousand Distinguished Scholars Plan" of Jiangxi Province, Outstanding Young People of Jiangxi Province, expert of "Jiangxi Navigator" Think Tank, evaluation expert of high-tech enterprises in Jiangxi Province, and member of Applied Pharmacology of Jiangxi Pharmaceutical Society. The new drug research and development project I participated in completed the transformation of results, with a total amount of more than 200 million yuan. The BRD4 I participated in won the national major special support, and the c-Met project I participated in carried out the clinical phase II.

Fund

【Host】

1. The second batch of "Thousand Distinguished Scholars Plan" long-term project for innovative leading talents in Jiangxi Province - Youth category, 1 million RMB , 2020.1-2023.12, Fund number, jxsq2019101064, under research.
2. Jiangxi Provincial Science Fund for Distinguished Young Scholars , Research on Inhibiting SARS-CoV-2 Main Protease with Traditional Chinese Medicine, 2021.01.01-2023.12.31, 200,000 RMB, Fund number: 20212ACB216001, under research.
3. Structural analysis of anti-tumor target PARP7 and development of structure-based small molecule inhibitors, Jiangxi Provincial Department of Education, Jiangxi Provincial Key Research and Development Program, Fund No. 20203BBG73063, 2020.12.01-2023.11.30, 100,000 RMB, ongoing research.
4. Research and development of structure-based anti-tumor target PARP16 lead drug, Science and Technology Department of Ganzhou, Research and Development Program, Fund No. 60 of Gan Kefa [2020], 2020.7-2022.6, 100,000 RMB, under research.
5. Discovery and optimization of atherosclerosis inhibitors targeting PARP14, Cardio-cerebrovascular diseases Special Project of the Ministry of Education, Fund number XN201904, 2020.1-2021.12 , 100,000 RMB, under research.
6. National Natural Science Foundation of China (Youth Foundation), the discovery of a new inhibitor of potential anti-tumor target Tankyrase and its mechanism of action, 230,000 RMB, Fund No. 81402850, concluded.

7. Study on the crystal structure of Trankyrase1 and 3-Aminobenzamide, Xi 'an Medical University, 30,000 RMB, Fund No. : 2015DOC23, Completed.

【Participation】

973:

1. National Basic Research Program of China "Structural Biology Technology and Method Research based on Shanghai Synchrotron radiation Light Source, fund number: 2011CB911100, 20 million RMB .

Subproject: Research and Application of Tiny crystal structure determination technology based on Fine focusing Synchrotron radiation beamline station, 5 million RMB , completed.

2. National Natural Science Foundation of China (Youth Foundation), Research on Cubic phase crystallization method of membrane protein Lipid, Fund No. : 31000389, completed.

3. National Natural Science Foundation of China (Youth Foundation), Research on the Structure and Function of human Golgi protein GRASP55, Fund number: 31100528, completed.

4. National Natural Science Foundation of China (General Program), Research and development of anti-tumor drug HSP90 inhibitor based on fragment drug design method, Fund number: 81273368, completed.

5. Study on the Structure and function of Key Proteins in cardiovascular related signaling Pathways (No.2015RCYJ01), Xi 'an Medical University, High-level Talent Introduction Fund, 1 million RMB, 2015.07-2019.07, completed.

United States:

6. National Institutes of Health/National Institute Of Allergy and Infectious Diseases. Structure and mechanism of the ESX secretion system from pathogenic mycobacteria. Grant No. R01AI119022, 11.7 million RMB (\$1,693,125.00), 2015.07.25-2019.12.31. The question has been concluded.

Patents

1. New coronavirus SARS-Cov-2 Main protease and shikonin complex crystal and its preparation method, 202010688829.0.

2. Expression and purification method of PARP9, a target for breast cancer, 202010450875.7.

3. PARP15 protein and its inhibitor 3-amino-benzoyl complex crystal and its preparation method, 202010389140.8.

4. PARP15 protein and Niraparib inhibitor complex crystal and preparation method thereof, 202010797473.4.

Papers published

【First author or corresponding author】

1. **Jian Li***, Xuelan Zhou, Yan Zhang, Fanglin Zhong, Cheng Lin, Peter J. McCormick, Feng Jiang, Jun Luo, Huan Zhou, Qisheng Wang, Yang Fu, Jingjing Duan, Jin Zhang*. Crystal structure of

SARS-CoV-2 main protease in complex with natural product inhibitor shikonin illuminates a unique binding mode. *Science Bulletin*, 66(7),661-663, 2020. (*Corresponding Author). **Q1, IF:18.9.**

2. Zhuqing Zhang, Zuhao Guo, Xiaowei Xu, Danyan Cao, Hong Yang, Yanlian Li, Qiongyu Shi, Zhiyan Du, Xiaobin Guo, Xin Wang, Danqi Chen, Ying Zhang, Lin Chen, Kaixin Zhou, **Jian Li***, Meiyu Geng*, Xun Huang*, Bing Xiong*. Structure-Based Discovery of Potent CARM1 Inhibitors for Solid Tumor and Cancer Immunology Therapy. *J Med Chem.* 64, 16650–16674, 2021. (*Corresponding Author), **Q1, IF:7.3.**
3. **Jian Li** , Cheng Lin , Xuelan Zhou , Fanglin Zhong , Pei Zeng , Peter J. McCormick , Haihai Jiang* and Jin Zhang*. Structural Basis of Main Proteases of Coronavirus Bound to Drug Candidate PF-07304814. *Journal of Molecular Biology*. 434 (16) , 167706, 2022. **Q1, IF:5.6.**
4. Xuelan Zhou#, Fanglin Zhong#, Cheng Lin, Xiaohui Hu, Yan Zhang, Bing Xiong, Xiushan Yin, Jinheng Fu, Wei He, Jingjing Duan, Yang Fu, Huan Zhou, Peter J. McCormick, Qisheng Wang*, **Jian Li*** and Jin Zhang*. Structure of SARS-CoV-2 main protease in the apo state. *Science China Life Sciences*, 64(4), 656-659, 2020. (*Corresponding Author). **Q1, IF:9.1.**
5. Xiaojing Song#, **Jian Li**#, Miao Tian#, Huaiyi Zhu, Xiaohui Hu, Yuting Zhang, Yanru Cao, Heyang Ye, Peter J. McCormick, Bo Zeng, Yang Fu, Jingjing Duan, Jin Zhang. Cryo-EM structure of mouse TRPM2 in lipid nanodiscs. *Journal of Biological Chemistry*, 298 (2) , 101487 , 2022. (# equally contributed to the work). **Q2, IF:4.8.**
6. Yuting Zhang, Hongxia Gao, Xiaohui Hua, Qisheng Wang, Fanglin Zhong, Xuelan Zhou, Cheng Lin, Yang Yang, Junkang Wei, Weian Du, Huaiqiu Huang, Huan Zhou, Wei He, Hua Zhang, Yuting Zhang, Peter J. McCormick, Jinheng Fu , Dan Wang, Yang Fu, Xiaolu Lu, Tengfei Zhang, Jingjing Duan, Bingjie Qin, Haihai Jiang, Jun Luo, Yan Zhang, Qi Chen, Qunfeng Luo, Lin Cheng, Zheng Zhang , Jin Zhang*, **Jian Li***. Structure-based discovery and structural basis of a novel broad-spectrum natural product against main protease of coronavirus. *Journal of Virology*, 96(1), e01253-21, 2022, (*Corresponding Author). **Q2, IF:5.4.**
7. Jian Li, Cheng Lin, Xuelan Zhou, Fanglin Zhong, Pei Zeng, Yang Yang, Yuting Zhang, Bo Yu, Xiaona Fan, Peter J. McCormick, Rui Fu, Yang Fu, Haihai Jiang, Jin Zhang. Structural Basis of the Main Proteases of Coronavirus Bound to Drug Candidate PF-07321332. *Journal of Virology*, 96(8), e02013-21, 2022, (*Corresponding Author). **Q2, IF:5.4.**
8. Xiaohui Hu #, Cheng Lin#, Qin Xu#, Xuelan Zhou , Pei Zeng , Peter J. McCormick, Haihai Jiang, * **Jian Li** , * and Jin Zhang . *Structural Basis for the Inhibition of Coronaviral Main Proteases by a Benzothiazole-Based Inhibitor. *Viruses*, 14 (9) , 2075, 2022, **Q2, IF:4.7.**
9. Jingjing Duan#, Jian Li#, Gui-Lan Chen#, Yan Ge, Jieyu Liu, Kechen Xie, Xiaogang Peng, Wei Zhou, Jianing Zhong, Yixing Zhang, Jie Xu, Changhu Xue, Bo Liang, Lan Zhu, Wei Liu, Cheng Zhang, Xiao-Li Tian, Jianbin Wang, David E. Clapham, Bo Zeng, Zongli Li, Jin Zhang. Cryo-EM structure of TRPC5 at 2.8 Å resolution reveals unique and conserved structural elements essential for channel function. *Science advances*, 5(7):eaaw7935, 2019. (# equally contributed to the work). **Q1, IF:13.6.**
10. Jingjing Duan#, Zongli Li#, **Jian Li**#, Ana Santa-Cruz, Silvia Sanchez-Martinez, Jin Zhang* & David E. Clapham*. Structure of the full-length human TRPM4. *Proc Natl Acad Sci U S A.* 115(10), 2377-2382, 2018. (# equally contributed to the work). **Q1, IF:11.1.**
11. Jingjing Duan#, **Jian Li**#, Bo Zeng#, Gui-Lan Chen, Xiaogang Peng, Yixing Zhang, Jianbin Wang, David E. Clapham, Zongli Li*, Jin Zhang*. Structure of the mouse TRPC4 ion channel. *Nature Communications*, 9(1), 3102, 2018. (# equally contributed to the work). **Q1, IF:16.6.**
12. Junliang Wan#, **Jian Li**#, Sibali Bandyopadhyay, Samuel L. Kelly, Yang Xiang, Jin Zhang, Alfred H. Merrill, Jr., and Jingjing Duan. Analysis of 1-Deoxysphingoid Bases and Their N-Acyl

Metabolites and Exploration of Their Occurrence in Some Food Materials. *J Agric Food Chem.* 67(46):12953-12961, 2019(1022). **Q1, IF:6.1.**

13. Danqi Chen#, Aijun Shen#, **Jian Li#**, Feng Shi, Wuyan Chen, Jing Ren, Hongchun Liu, Yechun Xu*, Xin Wang, Xinying Yang, Yiming Sun, Min Yang, Jianhua He, Yueqin Wang, Liping Zhang, Min Huang, Meiyu Geng*, Bing Xiong*, Jingkang Shen*. Discovery of potent N-(isoxazol-5-yl)amides as HSP90 inhibitors. *Eur J Med Chem.* 87, 765-781, 2014. (# equally contributed to the work). **Q1, IF:6.7.**
14. **Jian Li**, Xu Zhang, Xiaojing Song, Rui Liu, Jin Zhang*, Zongli Li*. The Structure of TRPC ion channels. *Cell Calcium.* 80,75-79, 2019. **Q1, IF:4.0.**
15. Yixiang Chen, Xu Zhang, Tingting Yang, Ruixue Bi, ZhanmeiHuang, **Jian Li***, Jin Zhang*. Emerging structural biology of TRPM subfamily channels. *Cell Calcium.* 79, 25-28, 2019(0302). (*Corresponding Author). **Q1, IF:4.0.**
16. **Jian Li**, Lihua Sun, Chunyan Xu, Feng Yu, Huan Zhou, Yanlong Zhao, Jian Zhang, Jianhua Cai, Cheney Mao, Lin Tang, Yechun Xu, and Jianhua He*. Structure insights into mechanisms of ATP hydrolysis and the activation of human heat-shock protein 90, *Acta Biochimica et Biophysica Sinica.* 44(4), 300-306, 2012. **Q2, IF:3.7.**
17. **Jian Li**, Feng Shi, Danqi Chen, Huiling Cao, Bing Xiong, Jingkang Shen, and Jianhua He. FS23 binds to the N-terminal domain of human Hsp90: a novel small inhibitor for Hsp90. *NUCL SCI TECH*, 26, 108-114, 2015. **Q1, IF:2.8.**
18. Rui Liu, Xiaolu Lu, Xianhua Huang, Wei He, Jingjing Duan, Jin Zhang* **Jian Li***. Complex structure of human Hsp90N and a novel small inhibitor FS5. *NUCL SCI TECH*, 31, 30, 2020(0225). **Q1, IF:2.8.**
19. Pingyuan Wang#, **Jian Li#**, Xue Jiang, Zhiqing Liu, Na Ye, Youjun Xu, Guangfu Yang*, Yechun Xu*, Ao Zhang*. Palladium-catalyzed N-arylation of 2-aminobenzothiazole-4-carboxylates/carboxamides: facile synthesis of PARP14 inhibitors. *Tetrahedron.* 70, 5666-5673, 2014.(# equally contributed to the work). **Q3, IF:2.1.**
20. Jing Ren#, **Jian Li#**, Yueqin Wang#, Wuyan Chen, Aijun Shen, Hongchun Liu, Danqi Chen, Danyan Cao, Yanlian Li, Naixia Zhang, Yechun Xu, Mei-Yu Geng*, Jianhua He*, Bing Xiong*, Jingkang Shen*. Identification of a New Series of Potent Diphenol HSP90 Inhibitors by Fragment Merging and Structure-based Optimization. *Bioorg Med Chem Lett.* 24 (11), 2525-2529, 2014.(# equally contributed to the work). **Q2, IF:2.7.**
21. Huiling Cao#, Lihua Sun#, **Jian Li#**, Lin Tang, Huimeng Lu, Yunzhu Guo, Jin He, Yongming Liu, Xuzhuo Xie, Hefang Shen, Chenyan Zhang, Weihong Guo, Linjun Huang, Peng Shang, Jianhua He*, Dachuan Yin*. A quality comparison of protein crystals grown under containerless conditions generated by diamagnetic levitation, silicone oil and agarose gel. *Acta Crystallogr. D (Biol crystallogr.)*, 69(10), 1901-1910, 2013.(# equally contributed to the work). **Q2, IF:2.2.**
22. Hui-Ling Cao, Kai-Kai Lyu, Bin Liu, **Jian Li***, Jian-Hua He*. Discovery of a novel small inhibitor RJ19 targeting to human Hsp90. *NUCL SCI TECH*, 28, 70-77, 2017. (*Corresponding Author). **Q1, IF:2.8.**
23. Xuelan Zhou, Yang Yang, Qin Xu, Huan Zhou, Fanglin Zhong, Jun Deng, Jin Zhang *, **Jian Li ***. Crystal structures of the catalytic domain of human PARP15 in complex with small molecule inhibitors. *Biochemical and Biophysical Research Communications* ,622, (2022) ,93-100. **Q2, IF:3.1.**
24. Jingwen Feng a, Dongyang Li , Jin Zhang *, Xiushan Yin *, **Jian Li ***. Crystal structure of SARS-CoV 3C-like protease with baicalein. *Biochemical and Biophysical Research Communications.* 611 ,2022, 190-194. **Q2, IF:3.1.**

25. Hongxia Gao, Yuting Zhang, Haihai Jiang, Xiaohui Hu, Yuting Zhang, Xuelan Zhou, Fanglin Zhong, Cheng Lin, **Jian Li**,* Jun Luo* and Jin Zhang*. Crystal structures of human coronavirus NL63 main protease at different pH values, **Acta Crystallogr F Struct Biol Commun**, F77, 2021:348-355. (*Corresponding Author). **Q4, IF:0.9.**
26. Jian Zhou, Heyang Ye, Xiushan Yin, **Jian Li***. Research progress of tubulin affinity-regulated kinase 4 as a drug target. **Progress in Biochemistry and Biophysics**. 2022, 49 (8) : 1422~1430
27. Jian Zhou, Xianhua Huang, Jin Zhang, Xiaolu Lu, **Jian Li**. Research progress of potential anti-tumor and anti-inflammatory target PARP14, **Chinese Pharmacological Bulletin**, 2012, 38(3) : 347-54.
28. Jianle Wu #, Xiaolu Lu#, Shuigen Bian, Jinmei Zhu, Jin Zhang, Feng Jiang*, **Jian Li***. Research progress of potential drug target PARP16, **Progress in Biochemistry and Biophysics**, 2022, 49(3) : 553-560.·\
29. Yanru Zhou #, Weiwei Wang #, Pei Zeng #, Jingwen Feng, Dongyang Li, Yue Jing, Jin Zhang, Xiushan Yin, **Jian Li**, Heyang Ye *, Qisheng Wang *. Structural basis of main proteases of HCoV-229E bound to inhibitor PF-07304814 and PF-07321332. **Biochemical and Biophysical Research Communications**, 657:16-23, 2023, **Q2, IF:3.1.**
30. Jiqing Luo #, Weiwei Wang #, Haihai Jiang#, Wenwen Li, Pei Zeng, Jie Wang, Xuelan Zhou, Xiaofang Zou, Shenghui Chen *, Qisheng Wang *, Jin Zhang *, **Jian Li** *. Crystal structures of Main Proteases of SARS-CoV-2 variants bound to a Benzothiazole-Based Inhibitor. **Acta Biochimica et Biophysica Sinica**. 55 (8) : 1-8. 2023. **Q2, IF:3.7.**
31. Haihai Jiang#, Yanru Zhou#, Xiaofang Zou#, Xiaohui Hu, Jie Wang, Pei Zeng, Wenwen Li, Xiangyi Zeng, Jin Zhang, * and **Jian Li** *. Evaluation of the Inhibition Potency of Nirmatrelvir against Main Protease Mutants of SARS-CoV-2 Variants. **Biochemistry**. 2023. **Q3, IF:2.9.**
32. Cheng Lin#, Haihai Jiang#, Wenwen Li, Pei Zeng, Xuelan Zhou, Jin Zhang*, **Jian Li** *. Structural basis for the inhibition of coronaviral main proteases by ensitrelvir. **Structure**. 31, 1–9, 2023, **Q1, IF:5.7.**
33. Haihai Jiang#, Xiaofang Zou#, Pei Zeng, Xiangyi Zeng, Xuelan Zhou, Jie Wang, Jin Zhang* and **Jian Li** *. Crystal structures of main protease (M^{pro}) mutants of SARS-CoV-2 variants bound to PF-07304814. **Molecular Biomedicine**. 2023

【other】

34. Na Li, Hong Yang, Ke Liu, Liwei Zhou, Yuting Huang, Danyan Cao, Yanlian Li, Yaoliang Sun, Aisong Yu, Zhiyan Du, Feng Yu, Ying Zhang, Bingyang Wang, Meiyu Geng, **Jian Li**, Bing Xiong, *Shilin Xu, * Xun Huang, * and Tongchao Liu*. Structure-Based Discovery of a Series of NSD2-PWWP1 Inhibitors. **J Med Chem**. 65, 9459–94771, 2022, **Q1, IF:7.3.**
35. Catherine Chaton, Emily, Rodriguez, Robert, Reed, **Jian Li**, Cameron, Kenner and Konstantin, Korotkov. Structural analysis of mycobacterial homoserine transacetylases central to methionine biosynthesis reveals druggable active site. **Sci Rep**. 9(1):20267, 2019. **Q2, IF:4.6.**
36. Jianping Hu, Chang-Qing Tian, Mohammadali Soleimani Damaneh, Yanlian Li, Danyan Cao, Kaikai Lv, Ting Yu, Tao Meng, Danqi Chen, Xin Wang, Lin Chen, **Jian Li**, Shan-Shan Song, Xia-Juan Huan, Lihuai Qin, Jingkang Shen, Ying-Qing Wang, Ze-Hong Miao, and Bing Xiong. Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors. **J Med Chem**. 62(18):8642-8663, 2019. **Q1, IF:7.3.**

37. Zuhao Guo, Zhuqing Zhang, Hong Yang, Danyan Cao, Xiaowei Xu, Xingling Zheng, Danqi Chen, Qi Wang, Yanlian Li, **Jian Li**, Zhiyan Du, Xin Wang, Lin Chen, Jian Ding, Jingkang Shen, Meiyu Geng, Xun Huang, and Bing Xiong. Design and Synthesis of Potent, Selective Inhibitors of Protein Arginine Methyltransferase 4 against Acute Myeloid Leukemia. *J Med Chem.* 62(11):5414-5433, 2019. **Q1, IF:7.3.**
38. Jingjing Duan#, Zongli Li#, **Jian Li**, Raymond E. Hulse, Ana Santa-Cruz, Sunday A. Abiria, Grigory Krapivinsky, Jin Zhang* and David E. Clapham*. Structure of the mammalian TRPM7, a magnesium channel required during embryonic development. *Proc Natl Acad Sci U S A.* 115(35), E8201-E8210, 2018. (# equally contributed to the work). **Q1, IF:11.1.**
39. JianpingHu, YingqingWang, YanlianLi, DanyanCao, LinXu, ShanShanSong, MohammadaliSoleiman iDamaneh, **JianLi**, YueleiChen, XinWang, LinChen, JingkangShen, ZehongMiao, BingXiong*. Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups. *Eur J Med Chem.* , 150:156-175, 2018. **Q1, IF:6.7.**
40. Jing Ren, Min Yang, Hongchun Liu, Danyan Cao, Danqi Chen, **Jian Li**, Le Tang, Jianhua He, Yue-Lei Chen,* Meiyu Geng, Bing Xiong* and Jingkang Shen*. Multi-substituted 8-aminoimidazo[1,2-*a*]pyrazines by roebke-Blackburn-Bienaymé reaction and their Hsp90 inhibitory activity. *Org Biomol Chem.* 13(5):1531-1535, 2015. **Q2, IF:3.2.**
41. Yunzhu Guo, Lihua Sun, Dominik Oberthuer, Chenyan Zhang, Jianyu Shi, Jianglei Di, Baoliang Zhang, Huiling Cao, Yongming Liu, **Jian Li**, QianWang, Huanhuan Huang, Jun Liu, Janmirco Schulz, Qiuyu Zhang, Jianlin Zhao*, Christian Betzel*, Jianhua He*, Dachuan Yin*. Utilization of adsorption and desorption for simultaneously improving protein crystallisation success rate and crystal quality. *Sci Rep.* 4:7308, 2014. **Q2, IF:4.6.**
42. Yiquan Zou, Lei Xu, Wuyan Chen, Yiping Zhu, Tiantian Chen, Yan Fu, Li Li, Lanping Ma, Bing Xiong, Xin Wang, **Jian Li**, Jianhua He, Haiyan Zhang*, Yechun Xu*, Jia Li*, Jingkang Shen*. Discovery of pyrazole as C-terminus of selective BACE1 inhibitors. *Eur J Med Chem.* 68:270-83, 2013. **Q1, IF:6.7.**
43. Huan Zhou, Lihua Sun, **Jian Li**, Chunyan Xu, Feng Yu, Yahui Liu, Chaoneng Ji, Jianhua He*. The crystal structure of human GDP-L-fucose synthase. *Acta Biochim Biophys Sin (Shanghai).* 45(9):720-725, 2013. **Q2, IF:3.7.**
44. Lele Zhao, Danyan Cao, Tiantian Chen, Yingqing Wang, Zehong Miao, Yechun Xu, Wuyan Chen, Xin Wang, Yanlian Li, Zhiyan Du, Bing Xiong*, **Jian Li**, Chunyan Xu, Naixia Zhang, Jianhua He*, Jingkang Shen*. Fragment-based drug discovery of 2-thiazolidinones as inhibitors of the histone reader BRD4 bromodomain. *J Med Chem.* 56(10):3833-3851, 2013. **Q1, IF:7.3.**
45. Lihua Sun, Chunyan Xu, Feng Yu, Shixing Tao, **Jian Li**, Huan Zhou, Sheng Huang, Lin Tang*, Jun Hu, Jian-Hua He*. Epitaxial growth of Trichosanthin Protein crystals on mica surface. *Crystal Growth & Design.* 10(6):2766-2769, 2010. **Q1, IF:3.8.**
46. Duan-Zhuo Li, Shun-Fang Liu, Lan Zhu, Yu-Xing Wang, Yi-Xiang Chen, Jie Liu, Gang Hu, Xin Yu, **Jian Li**, Jin Zhang, Zhi-Xiang Wu, Han Lu, Wei Liu, and Bin Liu. FBXW8-dependent degradation of MRFAP1 in anaphase controls mitotic cell death. *Oncotarget.* 8(57): 97178-97186, 2017. **IF:4.345**
47. Huiling Cao, Kaikai Lyu, Bin Liu, Jian Li*, Jian-Hua He*. Discovery of a novel small inhibitor R J19 targeting to human Hsp90. *NUCL SCI TECH* 28:148, 2017. **Q1, IF:2.8.**
48. Danqi Chen, Yuehong Chen, Fulin Lian, Liu Chen, Yanlian Li, Danyan Cao, Xin Wang, Lin Chen , Jian Li, Tao Meng, Min Huang , Meiyu Geng , Jingkang Shen , Naixia Zhang , Bing Xiong. Fragment-based drug discovery of triazole inhibitors to block PDEd-RAS protein-protein interaction. *Eur J Med Chem.* 163,597-609, 2019. **Q1, IF:6.7.**

49. Zuhao Guo, Zhuqing Zhang, Hong Yang, Danyan Cao, Xiaowei Xu, Xingling Zheng, Danqi Chen, Qi Wang, Yanlian Li, Jian Li, Zhiyan Du, Xin Wang, Lin Chen, Jian Ding, Jingkang Shen, Mei-Yu Geng, Xun Huang, and Bing Xiong. Design and Synthesis of Potent, Selective Inhibitors of Protein Arginine Methyltransferase 4 Against Acute Myeloid Leukemia. **J Med Chem.** 62,5414-5433,2019. **Q1, IF:7.3.**
50. Hui-Ling Cao, Li-Hua Sun, Li Liu, Jian Li, Lin Tang, Yun-Zhu Guo , Qi-Bing Mei, Jian-Hua He, Da-Chuan Yin. a Structural consistency analysis of recombinant and wild-type human serum albumin. **J Mol Struct.**1127,1-5,2017. **Q2, IF:3.8.**